A radioactive tracer is a substance containing a small amount of a radioactive isotope that, once introduced into a system, can be followed from the outside by detecting the radiation it emits. In medicine, tracers are injected, swallowed, or inhaled so that cameras can map where they travel inside the body, revealing everything from tumor activity to blood flow in the heart. But medicine is only part of the story. The same principle lets hydrologists track water moving underground, agricultural scientists measure how plants absorb nutrients, and climate researchers date layers of ancient ice. The concept is simple: tag something with a radioactive atom, then watch where it goes.
How a Radioactive Tracer Actually Works
Every radioactive isotope decays at a known rate, releasing energy in the form of gamma rays, positrons, or other particles. A tracer exploits this by attaching a radioactive atom to a molecule that the body or environment handles in a predictable way. Because the radioactive version of the molecule behaves chemically the same as the stable version, it follows the same pathways, gets taken up by the same cells, and accumulates in the same places. The difference is that detectors outside the system can pick up the radiation and map exactly where the molecule ended up.
The choice of isotope depends on the job. For medical imaging, you want an isotope that emits radiation penetrating enough to escape the body and reach a camera, but that decays fast enough to limit the patient’s total radiation exposure. For environmental work, you might want an isotope that persists for years or even millennia so it can serve as a timestamp in slowly moving systems like groundwater or ice sheets. The isotope is paired with a carrier molecule chosen for where you want it to go: a sugar analog for cells that burn lots of glucose, a bone-seeking compound for skeleton scans, or a simple dissolved ion for tracing water flow.
Spotting Cancer With a Sugar Mimic
The most familiar medical use of radioactive tracers is the PET scan, short for positron emission tomography. The tracer used most often is a modified sugar molecule labeled with fluorine-18 (written as FDG, for fluorodeoxyglucose). You receive a small injection of FDG, wait about an hour while it circulates, and then lie inside a ring-shaped detector. Wherever FDG has accumulated, the fluorine-18 atoms decay and release positrons, which almost immediately collide with nearby electrons and produce pairs of gamma rays flying off in opposite directions. The PET scanner detects these pairs and uses their timing to pinpoint where each decay happened, building a three-dimensional map of tracer uptake throughout the body.
The reason FDG is so useful for cancer comes down to metabolism. Most cancers burn through glucose at an abnormally high rate, a behavior that has been recognized for decades. FDG mimics glucose closely enough that cancer cells gobble it up, but unlike real glucose, FDG gets trapped inside the cell after the first step of processing. The result is that tumors light up on the scan while surrounding healthy tissue stays relatively dim. This makes FDG-PET valuable for finding small tumors, checking whether a known cancer has spread, monitoring how well a treatment is working, and estimating prognosis across a range of cancer types.1PubMed Central. Mechanisms underlying 18F-fluorodeoxyglucose accumulation in colorectal cancer
FDG-PET is not perfect. Any tissue with high metabolic activity can take up the tracer, so inflammation, infection, and even normal brain tissue can produce bright spots that are not cancer. Interpreting PET scans takes experience and is usually combined with a CT or MRI scan to match the metabolic information with detailed anatomy. Still, the combination of PET and CT has become one of the most important tools in oncology over the past two decades.
The Workhorse of Hospital Imaging
While PET gets a lot of attention, the single most widely used radioactive tracer in clinical medicine is technetium-99m. It is the go-to isotope for SPECT imaging, which stands for single photon emission computed tomography. Unlike PET tracers, which emit positrons, technetium-99m emits a single gamma ray per decay, and SPECT cameras rotate around the patient to capture those gamma rays from multiple angles and reconstruct a 3D image.2Journal of Family Medicine and Clinical Research. Comparison Between Using Technetium-99m SPECT Imaging and Fluorine-18 PET Imaging
Technetium-99m has several qualities that make it almost ideal for routine hospital use. It has a half-life of about six hours, long enough to complete an imaging study but short enough that the radiation dose fades quickly. It emits gamma rays at an energy level that current cameras detect very efficiently. And it can be attached to a wide range of carrier molecules, which means hospitals use it for bone scans, heart perfusion studies, kidney function tests, thyroid imaging, and more. The sheer versatility of technetium-99m is the reason nuclear medicine departments worldwide depend on it for most of their day-to-day diagnostic work.
SPECT does have lower spatial resolution than PET, and it is generally slower. For situations where PET’s sharper images and more precise metabolic information are needed, fluorine-18 tracers are preferred. But SPECT equipment is cheaper, more widely available, and good enough for many clinical questions, which keeps technetium-99m at the center of the field.
Mapping Alzheimer’s and Other Brain Diseases
One of the more striking recent advances in radioactive tracer use has come from neurology. For much of medical history, the only definitive way to confirm Alzheimer’s disease was to examine the brain after death and look for the characteristic plaques and tangles. PET tracers have changed that. Researchers developed specialized molecules that bind to amyloid-beta, the protein that clumps into plaques in Alzheimer’s brains. When labeled with a positron-emitting isotope and injected into a patient, these tracers light up wherever amyloid deposits have formed, making it possible to detect a hallmark of the disease in a living person.
Amyloid PET imaging has been available in research settings for roughly two decades and is now approved for clinical use by the U.S. Food and Drug Administration, the European Medicines Agency, and regulatory bodies in other countries.3PubMed Central. The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review It has become a crucial diagnostic tool because it allows doctors to see amyloid plaques directly rather than relying solely on cognitive testing and clinical judgment.
The field has not stopped at amyloid. Newer tracers have been developed to bind to tau protein, another hallmark of Alzheimer’s, as well as markers of neuroinflammation.4PubMed. PET/CT of Dementia Tau PET imaging is especially promising because tau tangles correlate more closely with the location and severity of cognitive decline than amyloid plaques do. By combining amyloid PET and tau PET in the same patient, researchers can build a much more detailed picture of what is happening in the brain. This multimodal approach has deepened the understanding of not only Alzheimer’s but also other dementias, including Lewy body disorders and frontotemporal dementia.5PubMed Central. Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias The practical payoff is clearer: as new Alzheimer’s drugs that target amyloid reach the market, confirming that a patient actually has amyloid buildup before starting treatment becomes essential, and PET is the tool that does it.
When a Tracer Doubles as Treatment
In most imaging, the tracer’s only job is to be seen. But a growing field called theranostics flips this idea: the same targeting molecule that carries a diagnostic isotope can also carry a therapeutic one. You start by injecting a patient with a version of the molecule labeled with an imaging isotope to confirm that the tumor takes it up. If the scan shows strong uptake, you then give the same molecule labeled with a different isotope that emits short-range radiation capable of killing the cells it binds to.6PubMed Central. Theranostics in nuclear medicine practice
The most prominent example in current practice involves lutetium-177, a beta-emitting isotope used to treat certain neuroendocrine tumors and metastatic prostate cancers. Lutetium-177 is typically produced through neutron activation in nuclear reactors, though cyclotron-based production routes are also being explored.7PubMed Central. Assessment of 177Lu Production through 176Yb Target Bombardment using Deuteron Particles and Back-Shifted Fermi Gas Model The theranostic concept matters because it personalizes treatment at a fundamental level: you verify that the therapy will reach the target before delivering it, reducing the chance of giving a potent treatment to someone whose tumor would not respond.
Radioiodine therapy for thyroid disease is actually the oldest example of this approach, predating the term “theranostics” by decades. Iodine-131 concentrates naturally in thyroid tissue, so it can both image the thyroid (at low doses) and destroy overactive or cancerous thyroid cells (at higher doses). Radioiodine labeling methods have been refined over the years, using a variety of chemical strategies to attach radioactive iodine to molecules of interest.8PubMed. Radioiodine Labeling Reagents and Methods for New Chemical Entities and Biomolecules
Tracing Water Underground
Outside medicine, one of the longest-running applications of radioactive tracers is in hydrology. When you want to know how fast groundwater is moving, where it is being recharged, or how old the water in an aquifer is, radioactive isotopes offer a natural clock. Tritium (hydrogen-3), carbon-14, and chlorine-36 are among the isotopes commonly used to estimate recharge rates and residence times in aquifer systems.9Journal of Hydrology. A review of radioactive isotopes and other residence time tracers in understanding groundwater recharge: Possibilities, challenges, and limitations
Tritium is especially useful because large amounts of it entered the atmosphere during nuclear weapons testing in the 1950s and 1960s, creating a global “pulse” that seeped into groundwater. By measuring how much tritium remains in a water sample, hydrologists can estimate when that water last had contact with the surface. This technique has been applied worldwide, from measuring monsoon recharge in India’s Punjab state to mapping flow paths in deep confined aquifers.10Hydrology Research. Groundwater Recharge in Panjab State (India) Using Tritium Tracer
The approach has its limits. Most standard models assume that recharge and flow conditions have stayed roughly constant over time, a so-called steady-state assumption. When conditions change, interpreting the isotope data becomes much harder. Recent work has tested how well radioactive isotope tracers perform under transient conditions in confined aquifers, where recharge rates can shift significantly over the timescales the isotopes are tracking.11Geophysical Research Letters. Defining the Bounds of Using Radioactive Isotope Tracers to Sense Past Groundwater Recharge Under Transient State Conditions For water resource managers relying on these dating methods, knowing where the technique breaks down is just as important as knowing where it works.
Agriculture and Nutrient Uptake
Radioactive tracers have a quieter but substantial role in agricultural research. When scientists want to know exactly how much of a fertilizer a plant actually absorbs versus how much stays locked in the soil, they can use a radioactive form of the nutrient. Phosphorus-32, for example, is used to tag phosphorus fertilizer so that researchers can distinguish fertilizer-derived phosphorus from phosphorus already present in the soil.
Studies using this technique have measured phosphorus uptake efficiency in rice under different fertilization levels, helping quantify how well low-phosphorus soils supply the nutrient on their own and how efficiently added phosphorus is used.12Plant Science Today. Effect of phosphorus levels on yield, nutrient uptake and phosphorus utilisation efficiency in rice (Oryza sativa L.) using ³²P radiotracer technique under pot culture In forestry, the same isotope has been used in root bioassays to measure how quickly tree roots take up phosphorus. One study on loblolly pine found that trees growing in unfertilized soil absorbed phosphorus at a significantly higher rate than trees that had been fertilized at planting, suggesting the unfertilized trees’ roots had adapted to scavenge phosphorus more aggressively. The difference was seasonal, appearing during the growing months but disappearing by March.13Forest Science. Phosphorus Uptake Capacity of 14-Year-Old Loblolly Pine as Indicated by a 32P Root Bioassay
These kinds of tracer studies matter because phosphorus is a finite resource. Knowing exactly how efficiently plants use it under different conditions helps agronomists fine-tune fertilization strategies, reducing waste and environmental runoff without starving crops.
Reading Climate in Ice Cores
One of the more dramatic applications of radioactive tracers sits at the intersection of chemistry and climate science. Beryllium-10 is a cosmogenic isotope, meaning it is produced when cosmic rays strike atoms in Earth’s atmosphere. It falls to the surface and gets locked into layers of snow that eventually compact into glacial ice. By measuring beryllium-10 concentrations in ice cores, scientists can reconstruct both past cosmic ray intensity and past precipitation patterns.
Measurements from the Greenland Ice Core Project at Summit, Greenland, spanning more than 1,350 samples, showed that variations in beryllium-10 concentration are driven primarily by changes in precipitation rate linked to different climate regimes. The most striking feature was a sharp peak roughly 40,000 years ago, a signal that closely matched one found in the Vostok ice core from Antarctica. That correspondence allowed researchers to correlate climate records between the two poles with high precision, tying together Arctic and Antarctic climate histories in a way that few other methods can.14Journal of Geophysical Research: Oceans. Beryllium 10 in the Greenland Ice Core Project ice core at Summit, Greenland
Tracers in Veterinary Practice
Radioactive tracers are not limited to human patients. In veterinary medicine, nuclear imaging plays a growing role, especially in equine practice where lameness is common and its source can be hard to localize. Scintigraphy, the veterinary equivalent of a gamma camera scan, uses technetium-99m-labeled compounds to image large areas of the horse’s body and pinpoint regions of abnormal bone turnover or inflammation. It remains the only nuclear imaging technique routinely used for whole-body scanning in horses.
PET has also entered equine medicine, first used in horses in 2015. It offers higher-resolution, three-dimensional functional images but is currently limited to the lower limb, where it can detect subtle bone injuries before they become catastrophic fractures.15PubMed Central. Equine Nuclear Medicine in 2024: Use and Value of Scintigraphy and PET in Equine Lameness Diagnosis For racehorses and sport horses, catching a stress injury early can mean the difference between rest and recovery versus a career-ending break.
Why Some Patients Are Afraid of the Tracer
Despite the low doses involved, the word “radioactive” can trigger outsized anxiety. Some patients perceive the radiation risk from a diagnostic scan as so high that they refuse procedures their doctors consider critical.16Journal of Nuclear Medicine. Subjective Perception of Radiation Risk This is a real clinical problem, because skipping a necessary PET or SPECT scan can delay a cancer diagnosis or allow a treatable condition to progress.
The context that usually reassures patients: the radiation dose from a typical diagnostic nuclear medicine scan is comparable to what you receive naturally from background sources over the course of a year or two. The tracers are designed to decay quickly, and the body excretes most of the remaining material within hours to days. The dose from a single FDG-PET scan, for instance, is in the same ballpark as a CT scan of the abdomen. Unlike external radiation exposure, where the source stays in the environment, a tracer inside the body is decaying on a fixed schedule and is actively being flushed out. For the vast majority of patients, the diagnostic benefit far outweighs the small incremental radiation risk.
That said, radiation exposure is cumulative over a lifetime, so physicians do weigh the necessity of each scan. Pregnant women and young children warrant extra caution, and alternative imaging without radiation (such as MRI or ultrasound) is preferred when it can answer the clinical question just as well.
The Supply Chain Problem Few Patients Know About
A vulnerability lurking behind all of this technology is the supply chain for the isotopes themselves. Technetium-99m, the workhorse tracer described earlier, does not exist in nature and cannot be stockpiled. It is generated from molybdenum-99, which itself is produced primarily in a small number of aging nuclear research reactors around the world. When one of those reactors goes offline for maintenance or unexpected repairs, hospitals can face sudden shortages that force them to delay or cancel scans.17PubMed Central. Shortages no more: Fixing the isotope supply chain
This has happened multiple times over the past two decades, prompting governments and industry groups to invest in alternative production methods, including cyclotron-based approaches and new reactor designs. Progress has been real but slow, and the global medical tracer supply remains more fragile than most patients or even many physicians realize. For a substance that tens of millions of diagnostic procedures rely on each year, the mismatch between demand and production infrastructure is a persistent concern that the nuclear medicine community continues to push to resolve.